An indirect immunofluorescence assay is described which specifically detects antibodies against cervical carcinoma-associated membrane antigens. Cells from the ME-180 cervical carcinoma cell line were used as target cells. Sera had to be absorbed with pooled tonsillar lymphocytes prior to use, to remove nonspecific antibodies. The antibody was detected in 61 of 74 patients (82%) with invasive squamous cell carcinoma of the uterine cervix and in 5 of 65 controls (8%). A group of 49 patients with early or preneoplastic stages of this tumor (microinvasive carcinoma, carcinome-in-situ, and dysplasia) did not differ from the control group in the incidence of the antibody (5 of 49 patients, 10%). It is concluded that the occurrence of this antibody is specific for cervical carcinoma (P < 0.001). However, the assay cannot be used as a diagnostic marker for preneoplastic stages of this tumor.

A lymphocyte stimulation assay is described which detects immune reactivity to antigens derived from the CaSki cervical carcinoma cell line. Taking a stimulation index of greater than 4.1 as positive, the peripheral blood lymphocytes of 14/20 patients (70%) with untreated dysplasia or carcinoma-in-situ, 8/19 patients (42%) with untreated macroinvasive squamous cell carcinoma of the uterine cervix and 8/38 controls (21%) showed positive reactions. Statistical analysis revealed a significant difference between the group of patients with dysplasia or carcinoma-in-situ and the controls. The sera of patients and controls were simultaneously tested for the presence of tumour-directed antibody. There was no correlation between the occurrence of cellular immune reactivity and of serum antibody, both directed to cervical carcinoma antigens. Cellular immune reactivity tended to occur more frequently in patients with preinvasive stages of cervical carcinoma, and serum antibody in patients with macroinvasive carcinoma.